Engineered gene transcriptional repression tool targeting hepatitis b virus gene and use thereof

An engineered gene repression tool using a TALE domain for HBV gene targeting achieves precise epigenetic editing, addressing the need for improved HBV treatment by effectively repressing viral transcription.

HK40135124APending Publication Date: 2026-07-17EPIGENIC THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
EPIGENIC THERAPEUTICS INC
Filing Date
2026-05-08
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current treatments for hepatitis B virus (HBV) infection lack effective gene-specific targeting mechanisms to inhibit viral replication and expression, necessitating improved tools for precise epigenetic regulation.

Method used

An engineered gene transcription repression tool utilizing a transcription activator-like effector (TALE) domain and epigenetic modification domains for specific binding to HBV gene sequences, enabling targeted epigenetic editing.

Benefits of technology

The tool provides precise and effective repression of HBV gene transcription, potentially reducing viral load and improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000051_0000
    Figure 00000051_0000
  • Figure 00000051_0001
    Figure 00000051_0001
  • Figure 00000052_0000
    Figure 00000052_0000
Patent Text Reader

Abstract

Provided is an epigenetic editor comprising a transcriptional activator-like effector (TALE) domain, at least one epigenetic modification domain, and at least one transcriptional regulatory domain; wherein the TALE domain can be specifically combined with a target nucleotide sequence on an HBV (Hepatitis B Virus) gene and / or a regulatory element of the HBV gene.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580003679.6 (22) Application Date 2025.06.23 (66) Domestic Priority Data 202410816212.0 2024.06.21 CN 202411842301.9 2024.12.13 CN (85) PCT International Application Entering National Phase Date 2026.01.12 (86) PCT International Application Application Data PCT / CN2025 / 000022 2025.06.23 (87) PCT International Application Publication Data WO2026 / 007374 ZH 2026.01.08 (71) Applicant Yijielike (Shanghai) Biotechnology Co., Ltd. Address 200131 Unit 1, Building 4, 5th & 6th Floor, No. 160, Basheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai (72) Inventors: Peng Wenbo, Mao Shaoshuai, Feng Zhengyan, Zhao Junzheng, Wu Leilei, Sun Di (74) Patent Agency: Shanghai Dianshi Intellectual Property Agency (General Partnership) 31309 Patent Attorneys: Zhang Zheng, Jiang Fangwei (51) Int.Cl. C07K 19 / 00 (2006.01) C12N 15 / 113 (2006.01) C12N 15 / 51 (2006.01) C12N 15 / 63 (2006.01) A61K 48 / 00 (2006.01) A61P 31 / 20 (2006.01) (54) Invention Title: Engineered Gene Transcription Repression Tool Targeting Hepatitis B Virus Gene and Its Use (57) Abstract: An epigenetic editing agent is provided, comprising a transcription activator-like effector (TALE) domain, at least one epigenetic modification domain, and at least one transcription regulatory domain; wherein the TALE domain is capable of specifically binding to target nucleotide sequences on the HBV gene and / or regulatory elements of the HBV gene. CN 121568968 A 2026.02.24 CN 1 21 56 89 68 A